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Clozapine and all-cause mortality in
treatment-resistant schizophrenia: a
historical cohort study
Cho J, Hayes RD, Jewell A, Kadra G, Shetty H, MacCabe JH,
Downs J. Clozapine and all-cause mortality in treatment-resistant
schizophrenia: a historical cohort study.
Objective: Large-scale epidemiological studies have demonstrated a
protective effect of clozapine on mortality in people with schizophrenia.
Clozapine is reserved for use in patients with treatment-resistant
schizophrenia (TRS), but evidence of clozapine’s effect on mortality
exclusively within TRS samples is inconclusive. Hence, we aimed to
investigate the effect of clozapine use on all-cause mortality in TRS
patients.
Methods: A historical patient cohort sample of 2837 patients, who met
criteria for TRS between 1 Jan 2008 and 1 Jan 2016, were selected from
the South London and Maudsley NHS Foundation Trust (SLAM)
electronic health records (EHR). The national Zaponex Treatment
Access System (ZTAS) mandatory monitoring system linked to the
SLAM EHR was used to distinguish which patients were initiated on
clozapine (n = 1025). Cox proportional hazard models were used,
adjusting for sociodemographics, clinical monitoring, mental and
physical illness severity and functional status.
Results: After controlling for potential confounders, the protective
effect of clozapine on all-cause mortality was significant (adjusted
hazard ratio 0.61; 95% confidence interval 0.38–0.97; P = 0.04).
Conclusions: Clozapine reduces the risk of mortality in patients who
meet criteria for TRS. We provide further evidence that improving
access to clozapine in TRS is likely to reduce the mortality gap in
schizophrenia.
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Significant outcomes
• Among patients with treatment-resistant schizophrenia (TRS), clozapine users had a reduced mortal-
ity risk compared to patients who have not used clozapine, after taking account for differential base-
line risks including psychopathology and functional status, and addressing potential impact of
survival biases.
Limitations
• An automated approach was used to identify patients who meet TRS criteria and who have not been
previously trialled on clozapine. This might lead to misclassification, possibly including non-TRS
patients in the analysis. This misclassification is more likely to be non-differential.
• There is potential residual confounding by unmeasured confounders such as comorbid cardiovascu-
lar disease and smoking.
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Introduction
Patients with schizophrenia and other psychoses
have approximately three times higher rates of all-
cause mortality and over ten times higher rates of
suicide compared to general population (1).
A number of epidemiological studies have
recently examined how pharmacological treat-
ments may be associated with differences in sur-
vival in populations with psychoses. The effects
of clozapine, an atypical antipsychotic, on mor-
tality in patients with psychoses has received par-
ticular attention (2–9). Despite the varied
comparators and study populations, several large-
scale studies with long-term follow-up have
reported consistently a protective effect of clozap-
ine use on mortality (9). However, clozapine use
is restricted as a third-line treatment option in
most countries, and only licensed for patients
with treatment-resistant schizophrenia (TRS),
where first- and second-line antipsychotic treat-
ment trials have failed. Ahead of using clozapine,
patients undergo clinical examinations including
routine haematological screening to reduce the
risk of the rare but severe side-effect of agranulo-
cytosis (10). In most developed countries includ-
ing the United Kingdom, clozapine therapy can
only be initiated when minimum absolute neu-
trophil counts are achieved, followed by weekly
to monthly blood profile monitoring (11). Conse-
quently, clozapine users are likely to clinically dif-
fer from non-clozapine users. Moreover, patients
who meet the definition of treatment resistance
may be biologically distinct from those with treat-
ment-responsive schizophrenia (12–14). In line
with this, two recent studies have investigated the
effect of clozapine use on mortality in TRS (8,
15). The study using United States Medicaid data
reported no significant mortality difference
between those patients treated with clozapine and
those without (15), whereas the Danish national
registry study found an approximately twofold
higher mortality in non-clozapine users (8). With-
out further study, these contrasting findings from
two different healthcare systems make it difficult
to determine whether clozapine does or does not
reduce the risk of death in patients with treat-
ment-resistant schizophrenia.
Many patients who meet criteria for treatment
resistance either never receive clozapine treatment
or at least experience considerable delay in receiv-
ing it (16, 17).These studies imply a hesitation on
the part of clinicians and/or patients. Their
findings suggest barriers to earlier adoption of
clozapine might be due to concerns over severe
side-effects, and difficulties with adhering to strict
initiation guidelines and schedule of intensive clini-
cal monitoring. Patients with TRS, prior to clozap-
ine initiation, generally have complex treatment
regimes. In an earlier study, we found 14% of
patients with TRS on antipsychotic polypharmacy
and 33% receiving adjuvant psychotropic drugs
such as antidepressants and benzodiazepines (18).
These more complex treatment patterns are associ-
ated with greater harm than monotherapy regimes.
Antipsychotic polypharmacy has been associated
with increased risks of readmission (19), adverse
events such as extrapyramidal side-effects (20),
metabolic syndrome (21) and mortality (22, 23). In
terms of preventing potentially avoidable deaths, it
is important to discern whether clozapine is supe-
rior to other TRS regimens in reducing mortality.
If this effect is confirmed, there is a greater argu-
ment for helping patients with TRS start and
sustain clozapine treatment.
Aims of the study
The present historical cohort study investigates the
effect of clozapine use on all-cause mortality in
treatment-resistant schizophrenia patients in the
United Kingdom. Using electronic mental health
records from community and in-patient care set-
tings linked to clozapine national registry data, we
aimed to address several of the methodological
weaknesses identified by a recent systematic review
of prior work examining clozapine use and mortal-
ity in schizophrenia (9). These include issues of
residual bias through selecting non-treatment-
resistant schizophrenia controls (24), performance
bias through better access to care, survival bias (2)
and measurement bias through exclusion of hospi-
tal-based prescribing (25).
Material and methods
Data sources
Clinical record interactive search. The Clinical
Record Interactive Search (CRIS) has provided an
anonymized search system for the electronic health
records (EHR) of the South London and Mauds-
ley NHS Foundation Trust (SLAM) from 2007
onwards (25–27). SLAM provides mental health
specialist services in four London boroughs (Lam-
beth, Southwark, Lewisham and Croydon), cover-
ing roughly 1.36 million of population. Using the
Using the CRIS system, researchers can query
structured and free-text data of over 300 000
patients. These patient records are updated by con-
temporaneous national mortality information
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(irrespective of current treatment status in SLAM),
and enhanced by linkages to external clinical data-
base such as the national Zaponex Treatment
Access System (ZTAS) clozapine register.
ZTAS register. To prevent clozapine users from
agranulocytosis-related deaths, several countries
including the United Kingdom, the United States,
Australia and Canada operate a national registry
and monitoring system for clozapine users with
blood test results. Clozapine patients treated
within SLAM are enrolled on ZTAS (http://
www.ztas.co.uk), which is one of the UK manda-
tory monitoring systems. In order for clinicians
to prescribe clozapine, they must register clozap-
ine users on the ZTAS system, with patients’ pre-
treatment blood test results (white blood cell,
neutrophil, eosinophil and platelet counts). The
reference blood test results are categorized as
green (white blood cell, 3.5 9 109/L; neutrophil
2.0 9 109/L), amber (3.0–3.5; 1.5–1.9) and red
(<3.0; <1.5). Patients with ‘green’ blood test
results can be prescribed clozapine, within
10 days of this result. In this study, a linkage was
performed with all patients whose last recorded
pharmacy within the SLAM boroughs, and who
had been registered on the ZTAS monitoring ser-
vice between 1 Jan 2007 and 1 Jan 2016. These
data were used to confirm the initiation date of
clozapine users first identified from the CRIS
database.
Ethical considerations
The use of anonymized data from the CRIS data-
base for mental health research was approved by
Oxfordshire Research Ethics Committee C (08/
H0606/71+5), and governance is provided for all
projects and dissemination through a patient-led
oversight committee.
Study subjects
Please see Fig. 1 for a flow diagram describing
the sample selection. We used a previously-estab-
lished approach (2) to identify the initial cohort
which included all patients who received treat-
ment from SLAM services between 1 Jan 2007
and 1 Jan 2016, who were aged 15 years and
older, and had at least one recorded Interna-
tional Classification of Diseases version 10 (ICD-
10) diagnoses of schizophrenia (F20), schizoaffec-
tive disorder (F25) or bipolar disorder (F31)
recorded during the observation period. From
this cohort, we identified the six most commonly
used oral antipsychotic medications: amisulpride,
aripiprazole, haloperidol, olanzapine, risperidone,
quetiapine and any British National Formulary
listed long-acting injectable or depot (11). We
then identified those patients who had been pre-
scribed any of these antipsychotics and/or cloza-
pine. This yielded 14 972 subjects. Study subjects
were identified using both structured and free-
text fields in the CRIS system. For the free-text
data, subjects’ information was extracted using a
natural language processing (NLP) application
which was developed using Generalized Architec-
ture for Text Engineering (GATE). GATE
enables researchers to extract data from clinical
documents while considering the linguistic con-
text. The performance of this NLP application
for extracting medication prescribing has been
previously validated and found to have good
accuracy, for example identifying recorded cloza-
pine use at a patient level with the precision and
recall performance of 96% and 92% respectively
(2).
Identifying treatment resistance and clozapine exposure
Treatment-resistant psychosis patients were
defined as those who had ever been selected for
clozapine treatment or those who had received a
trial of at least three different antipsychotics, where
the third novel antipsychotic was initiated during
hospitalization between 1 Jan 2008 and 1 Jan 2016,
according to SLAM EHR and ZTAS records.
Among the initial cohort, 1042 subjects (the cloza-
pine exposed group) had greater than one ‘green’
blood profiles on the ZTAS records. The earliest
date was used as an indicative date for clozapine
initiation. For the non-clozapine group, 2089
patients met the definition of treatment resistance,
with no evidence of clozapine use. After excluding
2 subjects with invalid dates, 2087 treatment-resis-
tant patients with non-clozapine antipsychotic use
were identified. Among the identified clozapine
and non-clozapine groups, we then restricted the
sample to include only those who had received at
least one ICD-10 schizophrenia (F20) diagnoses
(Fig. 1).
Main outcome measure
All-cause mortality during the observation period
from 1 Jan 2008 to 31 Dec 2016 was determined
through routine nationwide mortality tracing
linked to the electronic health record. As previ-
ously described all previous and current SLAM
contacts are checked monthly against the national
mortality database and date of death is electroni-
cally flagged (2, 26).
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Follow-up
For the clozapine group, the ZTAS ‘green’ blood
result date was used as a proxy of the drug initi-
ation. To be recognized as valid, clozapine has
to be prescribed within 10 days of an initial
green result being registered on the ZTAS. This
provided the best marker for the date of clozap-
ine initiation in the ZTAS database. For the
non-clozapine group, the drug initiation date was
defined as the start date of the third antipsy-
chotic use on hospitalization. For each patient,
the follow-up time ended at the end of the obser-
vation window (31 Dec 2016) or with the
patient’s death, whichever occurred first. The fol-
low-up period was restricted to maximum five
years (1826.25 days).
Other exposure variables
Age calculation was based on age at initiation of
clozapine or the third novel antipsychotic.
Multiple deprivation index was used as a proxy of
socioeconomic status (27). This index was based
on a subject’s address group (area unit). Each area
unit has its population of 1500 residents on aver-
age, with various unit-level characteristics (em-
ployment, income, education, health, barriers to
housing and services, crime, living environment)
weighted according to the importance. In the pre-
sent study, the level of multiple deprivation was
divided into quartiles, and homeless and unknown
were given a category separately.
As a measure of clinical monitoring, clinical
contact days were calculated by summation of all
in-patient and out-patient visits during the follow-
up, in which one in-patient visit was counted as
one contact day regardless of the duration of
admission (2). Considering the varied follow-up
period in each subject, face-to-face clinical contact
days were divided by individual follow-up days,
and then the percentage was categorized into
quartiles.
Fig. 1. Selection of study subjects.
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The clozapine and non-clozapine groups were
meant to be clinically equivalent, but there is still a
possibility of selection bias because overall health
status can affect clozapine prescription. To address
this issue, the present study used the Health of the
Nation Outcome Scale (HoNOS) tool (28, 29), an
instrument used by clinicians to monitor the health
and wellbeing of psychiatric patients in the United
Kingdom. The HoNOS data were extracted based
on the date closest to the clozapine or 3rd antipsy-
chotic drug initiation date. HoNOS variables used
in this study were divided into three categories:
mental health symptom severity (overactive,
aggressive, disruptive or agitated behaviour, hallu-
cination and delusions and depressed mood), addi-
tional mental and physical health problems (non-
accidental self-injury, problems of drinking or
drug taking and physical illness or disability prob-
lems) and functional status (activities of daily liv-
ing, standard of living conditions, occupational
and recreational activities and social relationships).
Every variable was categorized as no, minor, mild,
moderate and severe problem. In addition, any
ICD-10 diagnoses F11 opiate and F10 alcohol use
related disorders, recorded before or during the
observation period, were also extracted from struc-
tured fields and free-text records.
Statistical analysis
All analyses were conducted using STATA version
12 (30). Chi-squared tests were used to make com-
parisons between the clozapine and non-clozapine
groups. To estimate the risk of mortality due to
clozapine use, Cox proportional hazard models
were used, in which the clozapine group was coded
as 1 and the non-clozapine group as 0. Our initial
multivariable model added sociodemographic vari-
ables as co-variates (age, gender, ethnicity, marital
status and deprivation level). We then added,
cumulatively, a number of co-variate sets as poten-
tial confounders. The sequence of adding these co-
variate sets followed the order used in a prior study
examining clozapine exposure and mortality (2).
These sets included a history of substance use dis-
orders (alcohol and opioid), clinical monitoring
(face-to-face contact days), mental health symp-
tom severity (agitated behaviour, hallucination
and delusions and depressed mood), additional
mental and physical health problems (non-acciden-
tal self-injury, problems of drinking or drug taking
and physical illness or disability problems) and
functional status (Activities of daily living [ADLs]
standard of living conditions, occupational and
recreational activities and social relationships).
Age was included in the Cox regression models as
a continuous variable, and the remaining variables
were treated as categorical variables. Hazard ratios
(HRs) and 95% confidence intervals (95% CIs)
were presented. Cox proportional hazard assump-
tions were checked via likelihood ratio tests to
examine whether there was interaction with time.
These tests were used to ensure that the relation-
ship between clozapine and mortality did not
change over time.
Results
The mean [standard deviation (SD)] follow-up
time was 1413.8 (559.2) days. A total of 2837 TRS
patients consisted of n = 1025 clozapine group and
n = 1812 non-clozapine group (Table 1). The
mean age was 38.7 years (SD, 11.4) and men
accounted for 62.5%. Characterized by mental
health symptom severity, 41.8% of subjects had
moderate or severe problems in hallucinations and
delusions, whereas 6.1% in depressed mood. The
proportion of deaths in subjects with moderate
problem of physical illness was higher (13.2%)
than those of other categories.
When comparing non-clozapine treatment-resis-
tant group with the clozapine group (Table 2), the
clozapine group had more frequent face-to-face
clinical contact (P < 0.001), but less severe baseline
psychopathology profiles (P < 0.001) than the
non-clozapine group. The clozapine group had
lower rates of substance use disorders, less severe
symptoms of agitation, drinking and drug prob-
lems, better indices of living conditions and social
relationships. The same tendency was observed
when we restricted the analysis to the subset of
participants with a HoNOS completed prior to
clozapine initiation date (Table S1).
Likelihood-ratio tests showed the proportional
hazards assumptions held (P = 0.39). The protec-
tive effect of clozapine use on 5-year mortality was
not significant in the crude Cox regression model
(HR, 0.73; 95% CI: 0.49–1.08; P = 0.12) (Table 3).
Adjustment for sociodemographic variables (HR,
0.60; 95% CI: 0.40–0.92; P = 0.02) showed cloza-
pine was significantly associated with a reduced
mortality. Further adjustment for history of sub-
stance use disorders, clinical monitoring frequency,
mental health symptom severity and additional
mental and physical health problems (HR, 0.66;
95% CI: 0.42–1.03; P = 0.07) demonstrated a simi-
lar, but non-significant effect – broadening confi-
dence intervals suggest reduced power due to
missing values reducing the available sample,
rather than significant attenuation of effect. The
final multivariable model, including all measured
covariates, showed a statistically significant
241
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protective effect of clozapine on all-cause mortality
(HR, 0.61; 95% 0.38–0.97; P = 0.04). Fig. 2 pro-
vides the survival probability curves during follow-
up for the clozapine and non-clozapine groups.
Discussion
We found a protective effect of clozapine use on
all-cause mortality in TRS patients over a 5-year
follow-up period. This is the first investigation to
Table 1. Characteristics of study subjects (N = 2837)
Total no.
(% of total sample)
No. of deaths (% per
characteristic)
Antipsychotic use
Clozapine 1025 (36.1) 35 (3.4)
Other antipsychotics 1812 (63.9) 75 (4.1)
Sociodemographic variables
Age (mean 38.7, standard deviation 11.4, range 17–71 years)
<35 years 1176 (41.5) 28 (2.4)
35–<55 years 1406 (49.6) 55 (3.9)
55 years or older 255 (9.0) 27 (10.6)
Gender
Women 1063 (37.5) 66 (3.7)
Men 1774 (62.5) 44 (4.1)
Ethnicity
White 1003 (35.4) 52 (5.2)
Black 1434 (50.6) 44 (3.1)
Asian 158 (5.6) 8 (5.1)
Mixed 237 (8.4) 6 (2.5)
Other or not stated 5 (0.2) 0 (0.0)
Marital status
Single 2327 (82.0) 93 (4.0)
Married or cohabiting 239 (8.4) 5 (2.1)
Divorced or separated 254 (9.0) 10 (3.9)
Not known or not disclosed 17 (0.6) 2 (11.8)
Deprivation level in area of residence
Quartile 1 (the highest) 590 (20.8) 23 (3.9)
Quartile 2 592 (20.9) 23 (3.9)
Quartile 3 588 (20.7) 18 (3.1)
Quartile 4 601 (21.2) 25 (4.2)
Homeless 101 (3.6) 1 (1.0)
Unknown 365 (12.9) 20 (5.5)
Substance use disorders
History of alcohol-related disorders
No 2679 (94.4) 99 (3.7)
Yes 158 (5.6) 11 (7.0)
History of opioid-related disorders
No 2778 (97.9) 108 (3.9)
Yes 59 (2.1) 2 (3.4)
Clinical monitoring
Face-to-face contact days (% of follow-up time)
Quartile 1 709 (25.0) 40 (5.6)
Quartile 2 711 (25.1) 23 (3.2)
Quartile 3 708 (25.0) 23 (3.2)
Quartile 4 (the highest) 709 (25.0) 24 (3.4)
Mental health symptom severity
Agitated behaviour
No problem 1138 (40.1) 41 (3.6)
Minor problem 646 (22.8) 22 (3.4)
Mild problem 508 (17.9) 18 (3.5)
Moderate problem 312 (11.0) 23 (7.4)
Severe problem 188 (6.6) 4 (2.1)
Missing 45 (1.6) 2 (4.4)
Hallucinations and delusions
No problem 511 (18.0) 15 (2.9)
Minor problem 378 (13.3) 12 (3.2)
Mild problem 718 (25.3) 30 (4.2)
Moderate problem 776 (27.4) 29 (3.7)
Severe problem 407 (14.4) 22 (5.4)
Missing 47 (1.7) 2 (4.3)
Depressed mood
No problem 1330 (46.9) 42 (3.2)
Minor problem 822 (29.0) 33 (4.0)
Mild problem 466 (16.4) 24 (5.2)
Moderate problem 139 (4.9) 8 (5.8)
Severe problem 35 (1.2) 1 (2.9)
Missing 45 (1.6) 2 (4.4)
Table 1. (Continued)
Total no.
(% of total sample)
No. of deaths (% per
characteristic)
Additional mental and physical health problems
Non-accidental self-injury
No problem 2450 (86.4) 97 (4.0)
Minor problem 164 (5.8) 6 (3.7)
Mild problem 94 (3.3) 3 (3.2)
Moderate problem 54 (1.9) 2 (3.7)
Severe problem 29 (1.0) 0 (0.0)
Missing 46 (1.6) 2 (4.3)
Problem-drinking or drug taking
No problem 1930 (68.0) 78 (4.0)
Minor problem 286 (10.1) 12 (4.2)
Mild problem 285 (10.1) 10 (3.5)
Moderate problem 216 (7.6) 6 (2.8)
Severe problem 69 (2.4) 2 (2.9)
Missing 51 (1.8) 2 (3.9)
Physical illness or disability problems
No problem 1824 (64.3) 53 (2.9)
Minor problem 459 (16.2) 14 (3.1)
Mild problem 341 (12.0) 21 (6.2)
Moderate problem 129 (4.6) 17 (13.2)
Severe problem 40 (1.4) 3 (7.5)
Missing 44 (1.6) 2 (4.5)
Functional status
Activities of daily living (ADLs)
No problem 1111 (39.2) 33 (3.0)
Minor problem 714 (25.2) 23 (3.2)
Mild problem 600 (21.2) 37 (6.2)
Moderate problem 299 (10.5) 13 (4.3)
Severe problem 66 (2.3) 2 (3.0)
Missing 47 (1.7) 2 (4.3)
Standard of living conditions
No problem 1512 (53.3) 50 (3.3)
Minor problem 528 (18.6) 27 (5.1)
Mild problem 351 (12.4) 15 (4.3)
Moderate problem 181 (6.4) 7 (3.9)
Severe problem 175 (6.2) 6 (3.4)
Missing 90 (3.2) 5 (5.6)
Occupational and recreational activities
No problem 1060 (37.4) 41 (3.9)
Minor problem 691 (24.4) 27 (3.9)
Mild problem 660 (23.3) 21 (3.2)
Moderate problem 237 (8.4) 14 (5.9)
Severe problem 102 (3.6) 3 (2.9)
Missing 87 (3.1) 4 (4.6)
Social relationships
No problem 874 (30.8) 31 (3.5)
Minor problem 713 (25.1) 22 (3.1)
Mild problem 754 (26.6) 31 (4.1)
Moderate problem 331 (11.7) 18 (5.4)
Severe problem 117 (4.1) 5 (4.3)
Missing 48 (1.7) 3 (6.3)
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use electronic clinical notes (enhanced by linked
data provided by a clozapine regulatory body) to
describe the association of clozapine with all-cause
mortality in TRS. These data from a comprehen-
sive specialist mental health care service within a
Table 2. Characteristics of clozapine and other antipsychotic groups in patients
with treatment-resistant schizophrenia
Clozapine
(N = 1025)
Non-clozapine
(N = 1812) P†
Sociodemographic variables
Age, mean (standard deviation) 39.2 (10.7) 38.4 (11.8)
<35 years 385 (37.6) 791 (43.7) <0.001
35 to <55 years 561 (54.7) 845 (46.6)
55 years or older 79 (7.7) 176 (9.7)
Gender 0.002
Women 679 (66.2) 1095 (60.4)
Men 346 (33.8) 717 (39.6)
Ethnicity <0.001
White 456 (44.5) 547 (30.2)
Black 422 (41.2) 1012 (55.8)
Asian 61 (6.0) 97 (5.4)
Mixed 84 (8.2) 153 (8.4)
Other or not stated 2 (0.2) 3 (0.2)
Marital status 0.084
Single 863 (84.2) 1464 (80.8)
Married or cohabiting 82 (8.0) 157 (8.7)
Divorced or separated 74 (7.2) 180 (9.9)
Not known or not disclosed 6 (0.6) 11 (0.6)
Deprivation level in area of residence <0.001
Quartile 1 (the highest) 212 (20.7) 378 (20.9)
Quartile 2 213 (20.8) 379 (20.9)
Quartile 3 171 (16.7) 417 (23.0)
Quartile 4 199 (19.4) 402 (22.2)
Homeless 22 (2.1) 79 (4.4)
Unknown 208 (20.3) 157 (8.7)
Substance use disorders
History of alcohol-related disorders 0.059
No 979 (95.5) 1700 (93.8)
Yes 46 (4.5) 112 (6.2)
History of opioid-related disorders 0.005
No 1014 (98.9) 1764 (97.4)
Yes 11 (1.1) 48 (2.6)
Clinical monitoring
Face-to-face contact days
(% of follow-up time)
<0.001
Quartile 1 183 (17.9) 526 (29.0)
Quartile 2 183 (17.9) 528 (29.1)
Quartile 3 263 (25.7) 445 (24.6)
Quartile 4 (the highest) 396 (38.6) 313 (17.3)
Mental health symptom severity
Agitated behaviour <0.001
No problem 567 (55.3) 571 (31.5)
Minor problem 220 (21.5) 426 (23.5)
Mild problem 126 (12.3) 382 (21.1)
Moderate problem 56 (5.5) 256 (14.1)
Severe problem 34 (3.3) 154 (8.5)
Missing 22 (2.1) 23 (1.3)
Hallucinations and delusions <0.001
No problem 218 (21.3) 293 (16.2)
Minor problem 153 (14.9) 225 (12.4)
Mild problem 291 (28.4) 427 (23.6)
Moderate problem 227 (22.1) 549 (30.3)
Severe problem 113 (11.0) 294 (16.2)
Missing 23 (2.2) 24 (1.3)
Depressed mood 0.002
No problem 495 (48.3) 835 (46.1)
Minor problem 309 (30.1) 513 (28.3)
Mild problem 159 (15.5) 307 (16.9)
Moderate problem 31 (3.0) 108 (6.0)
Severe problem 9 (0.9) 26 (1.4)
Missing 22 (2.1) 23 (1.3)
Table 2. (Continued)
Clozapine
(N = 1025)
Non-clozapine
(N = 1812) P†
Additional mental and physical health problems
Non-accidental self-injury 0.096
No problem 901 (87.9) 1549 (85.5)
Minor problem 52 (5.1) 112 (6.2)
Mild problem 27 (2.6) 67 (3.7)
Moderate problem 15 (1.5) 39 (2.2)
Severe problem 8 (0.8) 21 (1.2)
Missing 22 (2.1) 24 (1.3)
Problem-drinking or drug taking <0.001
No problem 752 (73.4) 1178 (65.0)
Minor problem 105 (10.2) 181 (10.0)
Mild problem 80 (7.8) 205 (11.3)
Moderate problem 57 (5.6) 159 (8.8)
Severe problem 6 (0.6) 63 (3.5)
Missing 25 (2.4) 26 (1.4)
Physical illness or
disability problems
<0.001
No problem 596 (58.1) 1228 (67.8)
Minor problem 196 (19.1) 263 (14.5)
Mild problem 146 (14.2) 195 (10.8)
Moderate problem 55 (5.4) 74 (4.1)
Severe problem 10 (1.0) 30 (1.7)
Missing 22 (2.1) 22 (1.2)
Functional status
Activities of daily living (ADLs) 0.219
No problem 402 (39.2) 709 (39.1)
Minor problem 269 (26.2) 445 (24.6)
Mild problem 210 (20.5) 390 (21.5)
Moderate problem 103 (10.0) 196 (10.8)
Severe problem 18 (1.8) 48 (2.6)
Missing 23 (2.2) 24 (1.3)
Standard of living conditions <0.001
No problem 637 (62.1) 875 (48.3)
Minor problem 186 (18.1) 342 (18.9)
Mild problem 88 (8.6) 263 (14.5)
Moderate problem 48 (4.7) 133 (7.3)
Severe problem 28 (2.7) 147 (8.1)
Missing 38 (3.7) 52 (2.9)
Occupational and
recreational activities
<0.001
No problem 433 (42.2) 627 (34.6)
Minor problem 269 (26.2) 422 (23.3)
Mild problem 195 (19.0) 465 (25.7)
Moderate problem 68 (6.6) 169 (9.3)
Severe problem 25 (2.4) 77 (4.2)
Missing 35 (3.4) 52 (2.9)
Social relationships <0.001
No problem 358 (34.9) 516 (28.5)
Minor problem 282 (27.5) 431 (23.8)
Mild problem 234 (22.8) 520 (28.7)
Moderate problem 97 (9.5) 234 (12.9)
Severe problem 32 (3.1) 85 (4.7)
Missing 22 (2.1) 26 (1.4)
†Pvalues represent the significance of difference between the clozapine and non-
clozapine groups, as assessed by chi-squared tests for categorical variables and the
student independent t test for continuous variables.
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geographic catchment, provided a greater depth of
information to characterize patients with TRS
than prior registry-based studies (8, 31). We over-
came the limitations of previous work by: restrict-
ing our analyses to TRS samples to reduce
selection bias; taking account of differential base-
line risks including psychopathology (hallucina-
tions, delusions, aggression, subclinical depression,
addiction) and functional status (problems with
ADL impairment, occupational and recreational
activities, social relationships, living conditions);
and addressing potential impact of survival biases.
The direction of effect we found was consistent
with a recent meta-analysis, which reported signifi-
cant pooled rate ratio of 0.34 in favour of patients
using clozapine (95% CI = 0.19–0.62, P ≤ 0.001)
comparing clozapine users to non-users and/or
other antipsychotic users (9). However, a previous
study including 29 823 patients with schizophrenia
in Sweden suggested that clozapine was not the
most favourable antipsychotic in terms of reducing
mortality, which may be attributable to more
restricted clozapine use in Sweden or methodologi-
cal difficulties access hospital prescribing data (25).
Focusing on TRS patients, Stroup et al. (31)
reported null findings, but they only followed their
study subjects (n = 3123) for one year (explaining
the relatively lower mortality rates across the total
sample) and used United States Medicaid data,
which has restricted coverage related to patients’
income and level of disability. Meanwhile, the
Danish study (n = 2370) (8) used the national reg-
istry covering all individuals in Denmark. This
study showed an adjusted HR of death related to
non-clozapine use of 1.88 (95% CI: 1.16–3.05),
which equates to reduced risk of mortality in the
clozapine group of 0.53, similar to the effect found
in the present study (HR = 0.61).
Clozapine is associated with improved treatment
outcomes in TRS patients (32–34) but polyphar-
macy or high doses of non-clozapine antipsy-
chotics predates clozapine treatment in around a
third of treatment-refractory patients, leading to
delayed clozapine initiation (17). In the present
study, we found 42% of the clozapine group had a
possible delay in clozapine initiation (i.e., clozap-
ine use after three or more attempts of non-cloza-
pine antipsychotics). Although beyond the scope
of this study, future analyses should examine,
within the clozapine subset, whether the delay
between meeting TRS criteria and receiving cloza-
pine is associated with greater mortality rates.
Prior naturalistic studies in treatment-resistant
populations have demonstrated that those not
receiving clozapine often show characteristic differ-
ences from those receiving clozapine (9, 31). In our
study, we found the clozapine group had high but
less severe baseline psychopathology profiles than
the non-clozapine treatment-resistant group in a
number of domains, including less severe symp-
toms of agitation, drinking and drug problems,
adverse living conditions and poor social relation-
ships. These factors are unlikely to distort the pro-
tective effect we found of clozapine on mortality as
they were accounted for in the analyses. However,
these differences reveal the potential selection
effects for clozapine initiation, and suggest certain
phenotypic and environmental differences which
may be behind clozapine treatment delay. It is pos-
sible that these selection effects are due to patient
preference, but they also may be driven by health
service rationing. Potentially, clinicians are being
pragmatic and not attempting to trial certain
groups of highly morbid patients for clozapine ini-
tiation.
Strengths of this study include restriction of the
study population to patients with psychiatric treat-
ment consistent with treatment resistance,
Table 3. Hazard ratios of all-cause mortality related to clozapine use in patients
with treatment-resistant schizophrenia
Deaths/total N HRs (95% CIs) P
Crude 110/2837 0.73 (0.49–1.08) 0.12
Multivariate Cox proportional hazard
models adjusted for
Sociodemographic variables 110/2837 0.60 (0.40–0.92) 0.02
Plus history of substance
use disorders
110/2837 0.61 (0.40–0.93) 0.02
Plus clinical monitoring 110/2837 0.67 (0.43–1.03) 0.07
Plus mental health symptom severity 108/2788 0.71 (0.46–1.11) 0.14
Plus additional mental and
physical health problems
108/2783 0.66 (0.42–1.03) 0.07
Plus functional status 104/2720 0.61 (0.38–0.97) 0.04
HR, hazard ratio; 95% CI, 95% confidence interval.
Fig. 2. Survival curves of all-cause mortality in patients with
treatment-resistant schizophrenia, stratified by antipsychotic
use.
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adjustment for an array of potential demographic
and clinical confounders, and the use of a compar-
ison group receiving active treatment. Further-
more, the present study used data covering all
mental health contacts in the catchment areas
(community and hospital care), with timely linkage
to accurate mortality data based on national regis-
ters. Specific to this study, the SLAM EHR includ-
ing mortality data was linked to national ZTAS
clozapine registry, which enabled us to improve
identification of patients with clozapine initiation.
This study had a number of methodological lim-
itations. Cause of death data was not available for
analysis within our existing governance arrange-
ments. Registrar reports on death dates are
received by NHS organizations routinely from
local registrars; however, cause of data death is
administered separately by the Office National
Statistics, and is only available through specific
permissions, which has not been provided for this
linked data study. We used an automated
approach, similar to the previous study by Wim-
berley et al. (8), to identify those highly likely to
meet TRS criteria and who have not been previ-
ously trialled on clozapine. This might lead to mis-
classification, possibly including non-TRS patients
in the analysis. However, misclassification is more
likely to be non-differential because the assignment
of exposure status (prescribing clozapine) and
recording of outcome status (mortality tracing)
were independent of each other. There is still
potential residual confounding by unmeasured
confounders such as comorbid cardiovascular dis-
ease and smoking. Some previous studies found
the protective effect of clozapine on all-cause mor-
tality after adjustment of baseline history of car-
diovascular disease including ischaemic heart
disease (4, 6). However, after clozapine initiation,
the likelihood of having cardiometabolic illnesses
such as hypertension, diabetes mellitus and hyper-
lipidaemia may increase (15, 35, 36). Because of
the cardiovascular adverse effects of the drug, it is
possible that clinicians may more strongly advise
smoking cessation to clozapine users, with this
leading to reduced smoking behaviour (37). That
said an increased risk of cardiometabolic illnesses
does not necessarily lead to death, and a previous
study showed that smoking was not associated
with the risk of cardiovascular deaths in 10-year
follow-up of clozapine users (36). To obtain a valid
estimation for the pure effect of clozapine on mor-
tality, it would be useful to include healthy beha-
viours as time-dependent variables in analyses.
Dose information was not available in the current
dataset, as suggested by Torniainen et al. (23),
high doses of antipsychotics may be related to
cardiovascular mortality; but low or moderate
doses may not. Therefore, the reduced risk of mor-
tality linked to clozapine observed in this study
might be derived from the use of high-dose non-
clozapine antipsychotics in TRS patients. Finally,
a potential bias could have been introduced if the
clozapine group had a greater number of extracted
HoNOS scores from initial hospital treatment
stage than the non-clozapine groups. HoNOS
scores tend to be higher in newly hospitalized sam-
ples than those taken at point of discharge or in
the community. However, this potential bias is
unlikely to have impacted the results, as we found
no significant discrepancy in the distribution of
treatment stages for extracted HONOS scores
between clozapine and non-clozapine groups.
There are several potential pathways for the pro-
tective effect of clozapine on mortality. It may be,
from a whole clinical population perspective, that
the benefits of clozapine’s effectiveness in TRS at
reducing psychopathology over other antipsy-
chotics, outweighs its associated risk for later car-
diometabolic disease (35, 36, 38). Certainly,
reducing psychotic symptoms would provide more
opportunity for patients to adopt healthier life-
styles such as reduced smoking and drinking (6).
The effects of regular mandatory physical health
screening cannot be completely excluded. The
requirement for a patient’s white blood cell and
neutrophil to be within normal ranges in the Uni-
ted Kingdom, suggests that the clozapine TRS
group may have a healthier blood profiles com-
pared to the non-clozapine group. However,
abnormal blood profiles such as high leucocyte
which increase the risks for cardiovascular events
and all-cause mortality (39, 40) does not exclude
clozapine initiation. The intensity of clinical moni-
toring associated with clozapine use in TRS popu-
lations, may permit earlier detection and treatment
of incidental physical health problems compared
to non-clozapine TRS groups; although Hayes
et al.(2) did take account of this increased clinical
engagement and still found the protective effect of
clozapine on mortality remained. Finally, it is
possible that clozapine could enhance health by
reducing the risk of inflammation-related patho-
physiology (41). Animal studies have provided
consistent evidence on clozapine’s anti-inflamma-
tory effects in the periphery, compared to other
antipsychotics such as haloperidol, risperidone and
quetiapine (42). Whether through changes in life-
style or improving later immune/inflammatory
responses in patients with TRS postclozapine initi-
ation, further investigations are warranted to
examine what factors mediate the observed protec-
tive effect of clozapine on mortality.
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In summary, our findings suggest that in TRS,
clozapine users have a reduced mortality risk
compared to patients who have not received
clozapine treatment. We add to the burgeoning
evidence that suggests clozapine may help reduce
health inequalities experienced by individuals
with TRS, and ultimately improve their life-
expectancy (1, 9). Our findings support the argu-
ment for a re-evaluation of clozapine treatment
within clinical settings, especially for better
resourcing services which aim to improve the ini-
tiation and continuation of clozapine for patients
with TRS.
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